Global EditionASIA 中文双语Français
Home / China / Health

Asthma drug by GSK given green light for use in China

By Zhou Wenting in Shanghai | | Updated: 2024-01-11 16:50
Share - WeChat

Pharmaceutical company GSK announced on Wednesday that its novel targeted biological agent Nucala has been approved in China to treat a type of severe asthma.

Nucala will be used for maintenance treatment of severe eosinophilic asthma (SEA) in adults and adolescents aged 12 and above.

SEA accounts for the largest number of severe asthma cases.

The drug is expected to provide an advanced disease management approach for millions of Chinese patients suffering from this respiratory disease, said the company.

GSK said the approval was given following an independent, Phase III clinical trial involving Chinese patients that yielded positive results.

There are roughly 46 million adults in China who suffer from asthma, with about 6 percent suffering from severe asthma.

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349